In a meta-analysis of randomised and observational studies, semaglutide use was associated with a lower risk of heart failure than placebo or control.
In plain wordsIn pooled studies, semaglutide use was linked to a lower risk of heart failure than placebo or control.
- Peptide
- Semaglutide
- Outcome
- DecreaseHeart failure risk
- Study
n: not reported in source
- Comparator
- Placebo or control
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- Dose not stated
Measurements
- OR for heart failure
- 0.74 ratio
- semaglutide vs placebo or control
Source sentences
Overall, this meta-analysis shows that semaglutide use was associated with an decreased risk of HF (OR: 0.74; 95 % CI: 0.58 to 0.94, I2 45 %), compared to placebo or control groups.
1 context sentence(design, population, supporting numbers)
Six randomised clinical trials (n = 28,762 patients) and two observational studies were identified and considered eligible for this systematic review.